B19 parvovirus is pathogenic in humans. The virus propagates in the bone marrow, where it is cytotoxic to erythroid progenitor ceils. Antibodies appear in blood after infection and neutralize virus in vitro; infection appears to confer lasting immunity. The predominant immune response on immunoblot is to the minor capsid protein (VP1), which differs from the major capsid protein (VP2) by an additional 227 amino acids. We previously demonstrated that antisera directed to a fusion protein containing this unique region or to more limited fusion peptidee of 50-100 amino acids each neutralized virus. In the current work, we tested synthetic peptides of about 20 amino acids derived from the VP1 unique region for their ability to elicit a neutralizing antibody response in rabbits. Individual peptides were covalently linked to a lysine core to produce a multivalent antigen. Animals produced antibodies to all 13 synthetic peptides, as determined by ELISA. At 12 weeks, animals injected with one of three peptides --two from the far amino terminus and the third from the center of the unique region --had produced antibodies that completely neutralized virus; by 16 weeks, antisera elicited with another four peptides also were effective. In summary, we identified regions containing neutralizing epitopee within the first 80 amino acids and amino acids 148-205 of the unique region. Our data suggest that synthetic peptides might be useful vaccine reagents for protection against parvovirus infection in humans.
B19 parvovirus is the only member of the large Parvoviridae family to cause disease in humans (Young, 1993) . The identified target of infection is the erythroid progenitor celt of the marrow. Destruction of erythroid precursors in persons with underlying hemolysis results in transient aplastic crisis (Serjeant et aL, 1981) , in immunosuppressed patients, chronic anemia , and in the midtrimester infant, hydrops fetalis (Anderson et aL, 1988; Anand et aL, 1987) , or congenital anemia (Brown et al., 1994) . In normal persons, virus propagates in the marrow, but symptoms result from immune complex deposition, in the skin of children as fifth disease (Anderson and Cherry, 1987) and in the joints of adults as a rheumatic syndrome (White etaL, 1985; Simpson et aL, 1984) . B19 parvovirus also has been associated with myocarditis (Saint-Martin eta/., 1990) and vasculitis (Finkel et aL, 1994) .
Antibody formation accompanies acute parvovirus infection (Cohen et al., 1983; Anderson et aL, 1985) , and the humoral immune response appears to be dominant in limiting and preventing infection. The presence of specific IgG to B19 parvovirus has been presumed to indicate life-long immunity (Erdman et aL, 1991) . Administration of commercial immunoglobulin terminates persistent infection (Kurtzman et aL, 1989b; Frickhofen et aL, 1990) .
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A T cell response to B19 parvovirus, either lymphocyte proliferation (Kurtzman et aL, 1989a) or lymphokine production (Nistic6 and Young, unpublished data), has not been detected in vitro.
The single-stranded DNA genome of B19 parvovirus encodes two structural proteins, the major capsid (VP2) and minor capsid (VP1) proteins (Shade et al., 1986; Cotmore eta/., 1986; . VP1, of molecular weight 83 kDa, has an identical amino-acid sequence to VP2 protein, 58 kDa, except for an additional 227 amino acids at its amino-terminus. Sixty copies of the capsid proteins assemble into a capsid which naturally contains about 95% VP2 and 5% VP1 . By X-ray crystallography, B19 parvovirus capsids have a geometry similar to that of other icosahedral particles (Agbandje et aL, 1994) .
Although VP2 predominates in the capsid, VP1 is important in eliciting an appropriate immune response in humans and animals. In late convalescent human sera, the major antibody response on immunoblot is against VP1, not VP2 (Kurtzman et al., 1989a; Schwarz et aL, 1988) . Recombinant capsids consisting only of VP2 fail to elicit a neutralizing immune response in animals , and increasing proportions of VP1 in capsids results in more effective antibodies for protection of erythroid progenitors in tissue culture (Bansal et aL, 1992 ). An antiserum produced by immunization of rabbits with a fusion protein containing the entire unique region 0042-6822/95 $6.00
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sequence of VP1 neutralized the virus' activity; this antiserum also immunoprecipitated virions and empty capsids, establishing an external localization of at least a portion of the unique region . When rabbits were inoculated with 11 overlapping fusion proteins choser~ to span the entire VP1 capsid protein (therefore, including VP2), the VP1 unique and VP1-VP2 junction regions contained the strongest neutralizing epitopes (Saikawa et al., 1993) . Peptides from the most amino-terminal par[ of the unique region most rapidly elicited neutralizing antibodies. By immunizing rabbits with overlapping synthetic peptides, neutralizing epitopes in this region were identified and localized to two short peptides.
We have now systematically examined synthetic peptides from the entire VP1 unique region and the VP1-VP2 junction region for their ability to elicit a neutralizing antibody response in rabbits. Our results indicate that the unique region contains numerous neutralizing epitopes, clustered in particular at the amino-terminus (between amino acids 1 and 80) and in the center (amino acids 148-205); synthetic peptides representing these regions might be useful as a human vaccine against parvovirus infection.
MATERIALS AND METHODS

Synthetic peptides
Thirteen overlapping peptides (MP1-MP13) corresponding to amino acids (aa) 46 to 259 of the VP1 protein were designed, synthesized, and formulated in a multiple antigenic system (Tam, 1988) (Table 1) . Each peptide was composed of 22 aa and flanking peptides overlapped by 6 aa. Each peptide was covalently linked to an octabranched lysine matrix core. MP1-MP11 spanned the VP1 unique region except for the far amino-terminal region (aa 1-45), MP12 included the VP1-VP2 junction region, and MP13 spanned the amino terminus of VP2.
Immunization
For each peptide, three rabbits were initially inoculated by the subcutaneous route with 1 mg/rabbit of peptide emulsified in complete Freund's adjuvant. Booster injections were performed at 3, 6, 9, 12, and 14 weeks with 0.5 mg of antigen/rabbit in incomplete Freund's adjuvant. Sera were obtained from phelobotomies performed at the time of inoculation.
Immunoblot
Rabbit antisera were examined for reactivity to recombinant empty capsids that contained both VP1 and VP2 B19 parvovirus capsid proteins . Empty capsids were boiled in Laemmli sample buffer and the sample was then subjected to 7.5% polyacrylamide electrophoresis (SDS-PAG E) followed by electrotransfer onto a nitrocellulose membrane. The membrane was treated with Super Block blocking buffer (Pierce, Rockford, IL) for 2 hr at room temperature and then cut into 5-mm-wide strips. Each strip of membrane was incubated with an individual antiserum (1,1000 dilution) in 50 mM Tris-HCI, pH 7.5, 200 mM NaCI, and 0.05% Tween 20 (TBST) for 1 hr at room temperature. After washing membranes three times with TBST, primary antibodies were detected using alkaline phosphatase conjugatedgoat anti-rabbit IgG in TBST by incubation for 1 hr at room temperature, followed by color development in a substrate solution containing nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate p-toluidine salt (Gibco BRL Life Technologies, Gaithersburg, MD).
ELISA
An enzyme-linked immunosorbent assay (ELISA) was devised to evaluate the titer and reactivity of rabbit antisera, using recombinant empty B19 parvovirus capsids containing both VP1 and VP2 as antigens. The concentration of empty capsids was adjusted to 1 #g/ml in phosphate buffered saline (PBS), and 100 #l of aliquot was added to each well of Immulon II microtiter plates (Dynatech, Chantilly, VA), followed by incubation at 4 ° overnight. After blocking with Super Block blocking buffer (Pierce) for 2 hr at room temperature, 100 #1 of various dilutions of antiserum in PBS, 0.05% Tween 20 (PBST), were added. After incubation for 1 hr at room temperature, plates were washed three times with PBST, incubated with 100 /~1 of peroxidase-conjugated goat antirabbit IgG (diluted 1=7500; Promega, Madison WI) for 1 hr at room temperature. After washing with PBST, 100 #1 of substrate solution (1-Step Slow TMB-ELISA; Pierce) .was added; the enzyme reaction was stopped with 100 /~1 of 1 N H2SO4. Absorbance at 450 nm was measured by an automated microplate reader (Bio-Rad Laboratories, Hercules, CA). Nonspecific binding of antigen was determined by substituting for antigen with 3% bovine serum albumin (BSA); average binding activity for BSA was 0.081 + 0.004. Nonspecific binding of antisera was measured using each preimmune antiserum diluted 1=1600; the average binding activity of preimmune sera was 0.075 _+ 0.019.
Erythroid colony assay
The ability of antisera to neutralize B19 parvovirus cytotoxicity was assessed in erythroid colony assays using human bone marrow cells. Bone marrow was obtained from normal donors under a protocol approved by Institutional Review Board of the National Heart, Lung, and Blood Institute. Mononuclear cells were isolated from bone marrow cells in a FicolI-Hypaque gradient (Organon Teknika, Durham, NO) and washed three times with Is- were incubated with 50 #1 of 1,10 dilution of rabbit antiserum for 1 hr at 4 °. Thirty microliters of diluted human serum containing infectious B19 parvovirus was added to the cell mixture and allowed to incubate for another 1 hr at 4 °. The mixture was then cultured in standard colony culture medium for late erythroid progenitor cells (CFU-E)= 0.8% methylcellulose, 30% FCS, 1% BSA, and 10 mM 2-mercaptoethanol (Terry Fox Laboratory, Vancouver, Canada) supplemented with 10 units of recombinant human erythropoietin (Ortho, Raritan, N J). Colonies were counted after 7 -8 days of incubation at 37 ° in 6% 002 and 95% humidity. All colony assays were carried out in duplicate. Control cultures included bone marrow alone, bone marrow and virus, and bone marrow with a known neutralizing antibody or with preimmune rabbit sera.
R E S U L T S D e t e c t i o n of anti-B19 parvovirus antibodies by immunoblot
We synthesized 13 peptides of 22 amino acids each; overlapping sequences were chosen to span the VP1 unique and VP1 -VP2 junction regions (Table 1 ). The peptides were covalently linked to a polytysine backbone to produce a multivalent antigen. Three rabbits were inoculated with each peptide preparation, and production of antibodies to denatured B19 parvovirus capsid proteins was examined by immunoblot. Rabbit sera were obtained at 12 weeks, and each of 39 sera or 13 pooled sera from individual groups were tested (Fig. 1) . For animals inoculated with MP1-MP11, peptides that spanned aa 46-227 of the VP1 unique region, antisera specifically recognized the VP1 protein and did not react with VP2. Antisera against MP12, derived from sequence of the VP1 -VP2 junction region, showed reactivity to both VP1 and VP2. Antisera to M13, from within VP2, also reacted with both VP1 and VP2 (because VP1 contains these sequences). Although all the multiple antigenic peptides elicited an antibody response which recognized B19 capsid proteins, reactivity to VP1 protein was weak for antisera prepared against MP1 and very poor for antisera to MP6. When the 39 rabbit individual sera (obtained at 12 weeks) were assayed individually by immunoblot, sera against MP1 and MP6 showed similar weak reactivity (data not shown). All antisera showed strong binding to the multiple antigenic peptide immunogens in the same immunoblot assay (data not shown).
Binding and neutralizing activities of individual a n t i s e r u m Binding of antisera was assayed by ELISA, using empty but intact capsids as antigens in native conformation. Various concentrations of the 39 antisera obtained from bleeding at 12 weeks were tested. Although there was considerable variability in the results of sera within each group, antisera produced by immunization with MP1 and MP6 peptides showed low binding (data not shown). Sera were also tested from animals immunized with one of three peptides derived from the far amino terminus (previously reported (Saikawa et al., 1993) ), two FIG. 1. Immunoblot analysis of rabbit antisera raised to MP1 to MP13. Recombinant VP1 + 2 empty capsids were subjected to PAGE and electrotransferred to nitrocellulose membranes. Immunoblot was performed using rabbit antisera obtained at 12 weeks from primary inoculation in order to examine reactivity to capsid proteins using empty recombinant B19 parvovirus capsids containing both major and minor structural protein species. Lanes 1 to 13 show results with pooled antisera of individual groups of sera, each group from animals immunized with one of 13 multiple antigenic peptides, MP1 to MP13. Molecular weight markers are shown in kilodaltons (Kd) on the left. Anticipated positions of VP1 and VP2 are indicated by arrows. rabbits were inoculated with each peptide in an identical protocol to that used for MP1-13; neutralization data of these sera were previously reported (Saikawa et aL, 1993) , all showed binding activity similar to MP1 binding (F1, mean binding, 0.275; F2, 0.175; F3, 0.19).
Neutralizing activity of individual antisera were evaluated by erythroid colony assays in which human bone marrow cells are targets of virus infection. Antisera against MP1, MP2, and MP7 were highly protective of erythroid colony formation; antisera against MP3 and MP10 showed intermediate activity, and no significant neutralization was observed for antisera to MP4, MP6, or MP13 (data not shown). (For comparison, sera of animals inoculated with F1-F3, F3 was highly protective, one of two sera for F2 was protective, and F1 sera were not active (Saikawa et aL, 1993) ). Neutralizing ability of antisera did not parallel the binding activity of sera in immunoblot or ELISA.
Sera obtained from animals at 16 weeks, after initial inoculation and four booster injections, were compared to antisera obtained at 12 weeks. Pooled antisera from the three animals immunized with each peptide preparation were compared for binding and neutralizing activities (Fig. 2) . Antisera at 16 weeks showed slightly higher binding activities than 12-week antisera. MP7 peptide appeared to be most consistently immunogenic and MP1 and, in particular, MP6 were least immunogenic. In erythroid colony assays of neutralizing activity, of the antisera obtained at 12 weeks, three (against MP1, MP2, and MP7) were greatly protective for erythroid progenitor cells, while others showed only a little or no protective nature. However, increased neutralizing activities were observed for several antisera obtained from 16 weeks= sera against MP3, MP8, MP9, and MP10 were more than 50% protective, and antisera to MP5, MP6, MP11, MP12, and MP13 offered significant protection, preserving 20 to 40% of colony-forming cells from cytotoxicity. For antisera to MP4, little or no neutralizing activity was apparent even for 16-week collections.
Localization of neutralizing epitopes
In an earlier study, we immunized rabbits with fusion proteins and found that several strong neutralizing epitopes were clustered in the VP1 unique and VPI-VP2 junction regions (Saikawa et aL, 1993) . That study included preliminary experiments with three overlapping multiple antigenic peptides, there labeled F1 to F3, from the far amino-terminus, and we have combined data for F1-F3 with those obtained here using 13 overlapping multiple antigenic peptides as well as the larger fusion proteins VPFI-VPF6 (Fig. 3) . In general there was the expected correlation of neutralizing activities (at 12 weeks) of fusion proteins and peptides= (1) strong activity forVPF1 and its included four peptides, F2, F3, MP1, and M P2, and moderate activity for VPF2 and its two peptides, MP1 and MP2; (2) weak activity for VPF3, which contained only a single neutralizing peptide, MP7; (3) VPF4 and VPF6 showed no activity and lacked neutralizing epitopes also on peptide immunization. However, the fusion protein VPF5 elicited highly neutralizing antisera while its individual constituent peptides failed to provoke a neutralizing antibody response. Likely conformationally dependent neutralizing epitopes exist in this fragment.
Neutralizing activities of some antisera became apparent only at 16 weeks. There was no obvious correlation of neutralizing activity and computer-generated predictions of protein structure.
DISCUSSION
Although neutralizing epitopes have been localized within the sequence of the major capsid protein VP2 by analysis of binding of monoclonal antibody to synthetic peptides (Sato eta/., 1991a,b; Yoshimoto eta/., 199t) , we examined the unique region of VP1, the minor capsid protein, because of its immunodominance in the human immune response. The presence of multiple neutralizing linear epitopes within the VP1 unique region suggests that recognition of this region by antibodies is not as conformationally fixed as for VP2 epitopes. Antibody may interfere with a crucial step in the virus life cycle. VP1 is not involved in binding of the virus to its receptor (Brown et al., 1993) but, by analogy with poliovirus (Lee et al., 1993) and adenovirus 2 (Greber et al., 1993) , perhaps participates in unpackaging of genetic material.
Although a variety of immunologic data show that the unique region of VP1 is clearly externally presented, its precise relationship to the capsid is unknown. Neither VP1, which constitutes only a small portion of the virus structure, nor the most amino-terminal 38 aa of VP2 were visualized in crystals of canine parvovirus (Tsao et aL, 1991) . Binding of an antipeptide antibody to virus indicates that the immunogen must correspond to a surface region of the protein and therefore of the virus. By this criterion, we can infer from our peptide sera experiments that much of the unique region of VP1 is external. Low binding activity was only detected for four peptides from the far amino terminus (F1 -F3 (8aikawa eta/., 1993) and MP1), suggesting that the first approximately 70 amino acids of the unique region of VP1 may be relatively internal in the tertiary structure of native capsid (interpretation of the poor binding of MP6 is more problematic as this peptide did not elicit a strong antibody response to denatured capsid proteins).
Despite the absence of an animal model, in many respects the immune response to B19 parvovirus is better understood than immunity to other Parvoviridae. Results of experiments with canine parvovirus are of interest because the structure of this virus has been solved to less Antisera of three rabbits belonging to each group pooled. Binding activities of the pooled antisera at 12 weeks (A) and 16 weeks (B) were measured by ELISA using recombinant VP1 + 2 empty capsids. The pooled sera were diluted to two different concentrations (1=400 and 1:1600); OD values at 450 nm for the high-titer sera are not linear at a dilution of 1=400 (closed bars) but are linear at 1:1600 (dotted bar). Each bar represents a mean value _+ standard error for OD at 450 nm of two independent experiments. Neutralizing activity of pooled antisera at 12 weeks (C) and 16 weeks (D) were determined by erythroid colony assays. Results are expressed as percentages of erythroid colony numbers of the uninfected control. Each bar indicates a mean value _+ SE of at least three independent experiments. Control cultures with uninfected bone marrow cells in the experiments shown in (C) or (D) yielded 39 +_ 7 or 51 _+ 11 erythroid colonies/105 bone marrow cells, respectively. than 3-A, resolution (Tsao eta/., 1991) . For example, peptide mapping of antisera and monoclonal antibodies using nonapeptide sets indicated that the amino terminus of VP2 was an immunogenic domain and capable of eliciting neutralizing antibodies (Langeveld et al., 1993) , while fusion proteins from the carboxyl terminus were not effective in eliciting a neutralizing antibody response (Lopez de Turiso et al., 1991) . Two neutralizing epitopes were localized in loops 1 and 3 on the virion surface and therefore accessible to antibody binding (Langeveld et al., 1993) .
Fusion proteins derived from cloned canine parvovirus have been used as immunogens (Lopez de Turiso et aL, 1991) . Neutralizing monoclonal antibodies recognized canine VP2 only, but fusion proteins from the VP2 sequence, while immunogenic, were minimally protective of virus infection in vitro; in contrast, a peptide that contained 42 codons of VP1 unique region and the first 22 codons of VP2 elicited a VPl-specific antibody response in rabbits, and these sera neutralized canine parvovirus in vitro (Lopez de Turiso etaL, 1991) . At least one canine T cell clone obtained after immunization with virus recognized VP1 specifically (Rimmelzwaan et al., 1990) . Recently, protective vaccination of dogs with synthetic peptides was reported: the immunogen was two peptides 15 amino acids long, derived from the amino terminus of the major capsid protein (Langeveld et aL, 1994 ) (a region perhaps analogous to the B19 VP1-VP2 junction region). Extrapolation from canine parvovirus to B19 parvovirus is limited by major differences in the structure and biology of these two viruses.
However, by X-ray crystallographic studies, the major spike is absent from B19 parvovirus empty capsids . Empty canine parvovirus capsids composed of VP2 only were protective in dog vaccine trials (L6pez de Turiso et aL, 1992), but a neutralizing antibody response to B19 parvovirus empty capsids requires the presence of VP1 Bansal Summary of neutralizing activities of fusion and synthetic peptides. The ability of multiple antigenic peptides (MP1 to MP13) to elicit neutralizing activities for B19 parvovirus are compared to activity of fusion proteins (VPF1 to VPF6) and multiple antigenic peptides (F1 to F3)which were reported elsewhere (Saikawa eta/., 1993) . Neutralization as evaluated by erythroid colony assay were expressed as percentages of control colony numbers and scored as follows, 0-20% (-); 21 -40% (+); 41-60% (+), 61-80% (++); 81-100% (+ + +). For MP1 -MP13, data obtained from both 12-and 16-week antisera are shown; for VPF1 -VPF6 and F1-F3, only 12-week antisera were tested. et a/., 1992). Nevertheless, we can tentatively infer from the current experiments in rabbits that a single multivalent peptide or a mixture of such synthetic peptides derived from the unique region of VP1 would be an effective immunogen to protect humans against parvovirus infection. Further work to examine dosage and schedule of inoculation is required to determine the practicality of such an approach.
